

Supplemental Figure 1




Figure S1, Related to Fig. 1: Distribution of ILC2s in cuffs of multiple non-barrier organs. **(A)**. Schematic of IL-5Cre-tdtomato; R26-CAG-tdtomato (Ai14) lineage-tracker-mouse reporter line. **(B and C)** Flow cytometry analysis of mouse from **(A)** demonstrating >90% specificity **(B)** and ~90% sensitivity **(C)** of the reporter in lung, perigonadal adipose tissue (GAT), and spleen (Spln). **(D)** 2D thin-cut lung imaging of ILC2s (IL-5RFP⁺) in Collagen IV-negative arterial adventitial cuff. **(E)** 2D thin-cut imaging of ILC2s (IL-5 RFP⁺) and rare Th2 cells (IL-5 RFP⁺ CD4⁺, yellow arrowheads) in cuffs from pancreas, mesenteric adipose tissue (MAT), liver, uterus, small intestine (SI), and spleen. **(F)** 2D thin-cut imaging of (ILC2) IL-5 RFP⁺ cells and CCL19-Cre; R26-YFP⁺ SC in lung cuffs. **(B-F)** Images and flow cytometry plots are representative of three or more mice.

Supplemental Figure 2




Figure S2, Related to Fig. 1: Distribution of ILC2s in epithelial, serosal body-cavity sites, and secondary lymphoid organs (SLOs). **(A-C)** 2D thin-cut imaging of ILC2 (IL-5RFP⁺) in 'epithelial tissues', including **(A)** stomach at the boundary of the muscularis and mucosa layers, **(B)** small intestine (SI) villus and epithelial crypts (marked with Ki-67), and **(C)** skin hair follicles. **(D-E)** 2D thin cut-imaging of ILC2 (IL-5RFP⁺) in SLOs, including **(D)** mesenteric lymph node (MLN) and **(E)** peyers patches of the SI. **(F-I)** 2D thin-cut imaging of ILC2 in serosal body cavity membranes, including **(F)** peritoneal membrane, **(G)** visceral pleura of the lung, **(H)** pericardium of the heart, or **(I)** peritoneal surface of the uterus. In some cases, PDGFR α GFP⁺ stromal cells were also visualized as noted. Images are representative of two or more mice.

Supplemental Figure 3




Figure S3, Related to Figs 1-3: (A) 2D thin-cut imaging of ILC2 (IL-5RFP⁺ CD45⁺) and dendritic cells (DCs; CD45⁺ CD11c⁺ MHCII⁺) in gonadal adipose tissue (GAT), pancreas, stomach and lung. (B) 3D imaging from lung of a 200 μ m projection of (top) a large lung survey with PDGFR α GFP, SMA, IL-5 RFP, and Lyve1 showing airways, arteries, veins, and lymphatics. Images were analyzed by utilizing co-localization channels and surfacing in Imaris software. Surfaces were rendered on SMA⁺ airways, SMA⁺, Lyve1⁺ blood vessels, SMA⁻, Lyve1⁺ lymphatic vessels, GFP⁺ PDGFR α stromal cells, and IL-5 RFP⁺ ILC2s. (Bottom) A close up of an airway-artery bundle with surfaces in place. (C) Analysis of 3D images related to Fig 3A-D, demonstrating number of contacts per ILC2 (IL-5 RFP⁺) with the indicated stromal subset. (D-G) Localization of ILC2s, DC and Treg subsets, and IL-33⁺ ASCs in indicated tissues. (F) 3D rendering with zoom of a 200 μ m thick projection with IL-5 RFP⁺ ILC2, Tregs (FoxP3GFP⁺), and DCs (CD11c⁺ MHCII⁺). (D,G) 2D thin cut images of liver and (E) pancreas identified ILC2 (IL-5 RFP⁺) and Tregs (CD3 ϵ ⁺ FoxP3GFP⁺) in proximity to IL-33⁺ ASCs. (H-K) 2D-thin cut images from tissues showing localization of PDGFR α GFP cells and IL-5RFP⁺ ILC2s during postnatal developmental time points indicated; (H) P5 lung, (I) P10 liver, or (K) P2 small intestine. (J) Quantification of localization of cuff (left) and sinusoidal (blood-borne, right) ILC2s (IL5 RFP⁺) with PDGFR α GFP⁺ SCs in P10 liver. Images are representative of three or more mice.

Supplemental Figure 4




Figure S4, Related to Fig 4: IL-33mcherry reporter construction, validation, and analysis via imaging and flow cytometry **(A)** Diagram of the construction for the IL-33-H2B-mcherry nuclear localization IL-33 reporter **(B)** qPCR validation of *Il33* transcript from sorted cells of the indicated IL-33mcherry⁺ (red) and cherry- (black) populations. **(C)** Flow cytometry analysis of lungs from IL-33mcherry heterozygous mice, demonstrating (top) subsets of epithelia, endothelia (blood BEC and lymphatic LEC), and stromal subsets, with (bottom) breakdown of all IL-33mcherry⁺ cells within these categories. **(D)** Flow cytometry from indicated tissues pre-gated on all PDGFR α GFP⁺ stromal cells and demonstrating IL-33mcherry subset expression (or reporter negative wild-type gating control). **(E-G)** Thin-cut imaging of IL-33 expression in adventitial cuffs of **(E)** uterus (non-pregnant), **(F)** spleen, and **(G)** pancreas revealed PDGFR α ⁺ IL-33⁺ cells present in the cuff. **(H)** Flow cytometry analysis of pancreas from IL-33mcherry homozygous (red) or wild-type control (grey) mice identified a dominant mesenchymal subset of Sca1⁺ IL-33⁺ ASCs. Images and flow cytometry plots are representative of 3 experiments. **(B)** pooled data from 3 independent experiments.

Supplemental Figure 5




Figure S5, Related to Fig 5: scRNA seq of adipose tissue ASCs resemble lung ASCs. **(A)** Heatmap of mean expression values of top 50 genes in lung ASCs (cluster 5). Data is log- transformed. **(B)** Validation of *Col1a1* and *Ccl11* mRNA expression by qPCR on sorted IL-33⁺ and IL-33⁻ subsets of lung mesenchymal (PDGFR α ⁺), epithelial (EpCAM⁺) and endothelial (CD31⁺) cells. **(C)** Unsupervised clustering analysis of IL-33mcherry⁺ CD45⁻ cells from perigonadal adipose tissue (GAT) visualized with t-SNE. Each dot indicates an individual cell (total cell number: 2037). **(D)** Heatmap of mean expression values of top 50 genes in GAT ASCs. Data is log- transformed. **(E)** Gene expression of selected genes projected onto tSNE plots. **(F)** Heatmap of mean expression values of top 50 genes in GAT ASCs projected on total lung CD45⁻ cell clusters. Data is log-transformed and row normalized. Stars indicate the three lung mesenchymal clusters (4, 5, and 9) and correspond to those described in Fig 5E. **(G)** Unsupervised clustering analysis of aggregated lung samples (IL-33mcherry⁺ CD45⁻ cells) from naïve and 4 weeks post *N. Brasiliensis* infection visualized with t-SNE. Each dot indicates an individual cell (total cell number: 5287). Cells are colored based on clusters (left panel) or sample origin (right panel).

Supplemental Figure 6




Figure S6, Related to Fig 6: (A and B) Monolayers of ASCs (PDGFR α ⁺Sca1⁺, orange) and parenchymal enriched stromal cells (PDGFR α ⁺Sca⁻, blue) at **(A)** ILC2 seeding and **(B)** enumerated 7 days post-seeding. **(C)** Log-normalized *Tslp* reads per cell from lung IL-33mcherry⁺ scRNAseq clusters defined in Fig 5A. **(D)** ILC2s and **(E)** TSLP amounts in ASC-ILC2 7-day co-cultures from wild-type (WT), IL-33 deficient, or wild-type treated with anti-TSLP blocking antibody. **(F)** Day 5 ILC2 proliferation (CTV dilution) and apoptosis (annexin V) analysis from ILC2 supernatant cultures +/- anti-TSLP. **(G and H)** ASC expression of IL-13 receptor components, with **(G)** IL4R α , shown by flow cytometry, or **(H)** *Il13ra*, shown as log-normalized reads from scRNAseq in Fig 5E. **(I-J)** ASCs IL-33mcherry expression (GMFI) and **(K)** culture supernatant TSLP amounts after co-culture with the indicated lymphocytes or treatment with the indicated cytokines at 10ng/mL for **(I)** 5 or **(J and K)** 3 days. **(L)** IL-33mCherry expression and frequency of eosinophils (percent of CD45⁺ cells) in lungs from IL-33mcherry heterozygous mice treated with IL-13 or IL-4complex i.n. for seven days, analyzed 20hrs post final dose. **(M and N)** Thin cut lung images from naive mice and day 28 post *N. brasiliensis* infection and stained for the indicated markers, demonstrating accumulation of cuff ILC2s (IL5RFP⁺ CD3e⁻), IL-5⁺ Th2 cells (IL5RFP⁺ CD3e⁺), and total CD45⁺ hematopoietic cells. **(O)** ILC2s (IL-5RFP⁺ CD3e⁻) in spleen day 28 post *N. brasiliensis* or day 6 post IL-33 treatment (500ng x3). **(P-U)** Flow cytometry analysis of lungs from the indicated time points post *N. brasiliensis* infection, demonstrating **(P)** relative percent of PDGFR α GFP^{lo} cuff ASCs, **(Q)** total stromal cell IL-33mCherry expression, or **(R-U)** post-infection frequencies of **(R)** ILC2s, **(S)** Th2 cells, **(T)** GFP-dim ASCs, or **(U)** GFP-dim GP38⁺ ASC subset from control (*Il5-cre*) or ILC2 deficient (*Il5-cre*;R26-DTA) mice. All images and flow cytometry plots are representative of three or more mice, bar graphs are pooled data from 2-3 experiments.

Supplemental Figure 7




Figure S7, Related to Fig 7: (A) 2D thin-cut images of tamoxifen treated (x3 doses) *Gli1-creERT2*; R26-YFP from perigonadal adipose tissue (GAT), pancreas, spleen, and liver. (B and C) Percentage *Gli1*-YFP⁺ cells of indicated populations analyzed by flow cytometry from naive mice (black), IL-33 treated (x3 500ng doses over 6 days, grey), or day 12 post *N. brasiliensis* infection (blue). (D) qPCR analysis of *Gli1* from the indicated sorted SC subsets from lung (black, IL-33mcherry-negative; red, IL-33mcherry⁺). (E and

F) Flow cytometry analysis of ILC2 numbers (**E**) one week or (**F**) four weeks post tamoxifen induction of Gli1⁺ cell deletion. (**G-L**) Flow cytometry analysis of tamoxifen treated Gli1-deleter mice and littermate controls after (**J-L**) IL-33 treatment (500ng x3 and PBS controls or (**G-I**) *N. brasiliensis* infection PI D12-14. (**M**) qPCR on sorted stromal cells from lungs of *Gli1-creERT2*; IL-33 Flox mice. (**N**) 2D thin-cut imaging of lungs from *Gli1-creERT2*; IL-33 Flox and Cre-negative littermate controls, stained for IL-33. (**A,N**) Representative of three or more mice. (**B and C**) One representative of three experiments shown, (**D-M**) pooled data from three or more independent experiments, with individual mice shown. * p<0.05, ** p<0.01, or indicated.

Table S1, Related to Fig 5: Complete scRNAseq results for all clusters defined. Tabs for 1) lung IL-33mcherry⁺ 2) lung total CD45⁻ 3) GAT IL-33mcherry⁺ 4) Lung naïve and day 30 PI *N. brasiliensis* 5) DAVID GO analysis for total lung cluster 5 ASCs.

Movie S1, Related to Fig 1: Meningeal ILC2s: 3D

Movie S2, Related to Fig 1: Pancreas ILC2s: serial Z stack sections

Movie S3, Related to Fig 3: Lung ILC2s with cuff stromal cells: serial Z stack sections

Movie S4, Related to Fig 3: GAT ILC2s with IL-33 expressing stroma: 3D